IN2012CN10925A - - Google Patents
Info
- Publication number
- IN2012CN10925A IN2012CN10925A IN10925CHN2012A IN2012CN10925A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A IN 10925CHN2012 A IN10925CHN2012 A IN 10925CHN2012A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A
- Authority
- IN
- India
- Prior art keywords
- trifluoromethyl
- phenyl
- ethyl
- amino
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010128585 | 2010-06-04 | ||
| JP2010218299 | 2010-09-29 | ||
| PCT/JP2011/062751 WO2011152508A1 (ja) | 2010-06-04 | 2011-06-03 | 光学活性ジベンジルアミン誘導体及びその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012CN10925A true IN2012CN10925A (zh) | 2015-04-24 |
Family
ID=45066863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10925CHN2012 IN2012CN10925A (zh) | 2010-06-04 | 2011-06-03 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8906895B2 (zh) |
| EP (1) | EP2578574B1 (zh) |
| JP (1) | JP5555320B2 (zh) |
| KR (2) | KR20130111512A (zh) |
| CN (2) | CN102933559B (zh) |
| AU (1) | AU2011259929B2 (zh) |
| BR (1) | BR112012030787A2 (zh) |
| CA (1) | CA2801417C (zh) |
| EA (1) | EA024241B1 (zh) |
| ES (1) | ES2581557T3 (zh) |
| HK (1) | HK1179959A1 (zh) |
| IL (1) | IL223377A (zh) |
| IN (1) | IN2012CN10925A (zh) |
| MX (1) | MX338024B (zh) |
| PT (1) | PT2578574E (zh) |
| TW (1) | TWI492749B (zh) |
| WO (1) | WO2011152508A1 (zh) |
| ZA (1) | ZA201209372B (zh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012046681A1 (ja) * | 2010-10-04 | 2012-04-12 | 興和株式会社 | 脂質代謝関連ｍＲＮＡの発現抑制剤 |
| US9272966B2 (en) | 2010-07-22 | 2016-03-01 | Kowa Company, Ltd. | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane |
| US20140303198A1 (en) * | 2011-11-29 | 2014-10-09 | Kowa Company, Ltd. | Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity |
| WO2013081087A1 (ja) * | 2011-12-02 | 2013-06-06 | 興和株式会社 | 光学活性化合物の製造方法 |
| JPWO2013137371A1 (ja) * | 2012-03-15 | 2015-08-03 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN105246877A (zh) * | 2013-05-31 | 2016-01-13 | 兴和株式会社 | 具有二苄胺结构的嘧啶化合物的新形态 |
| JP2017528448A (ja) * | 2014-08-21 | 2017-09-28 | エスアールエックス カーディオ，エル エル シー | プロタンパク質コンバターゼであるスブチリシン／ケキシンタイプ９（ｐｃｓｋ９）のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法 |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| WO2016084950A1 (ja) * | 2014-11-28 | 2016-06-02 | 興和株式会社 | 医薬組成物 |
| KR20170087880A (ko) * | 2014-11-28 | 2017-07-31 | 코와 가부시키가이샤 | 의약 |
| JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
| CN113574055A (zh) * | 2019-01-18 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189208A (en) * | 1991-07-01 | 1993-02-23 | Ethyl Corporation | Ibuprofen resolution |
| JP5244095B2 (ja) | 2007-04-13 | 2013-07-24 | 興和株式会社 | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| WO2012046681A1 (ja) | 2010-10-04 | 2012-04-12 | 興和株式会社 | 脂質代謝関連ｍＲＮＡの発現抑制剤 |
-
2011
- 2011-06-03 KR KR1020137000104A patent/KR20130111512A/ko active Search and Examination
- 2011-06-03 CA CA2801417A patent/CA2801417C/en not_active Expired - Fee Related
- 2011-06-03 KR KR1020177017703A patent/KR20170078865A/ko not_active Application Discontinuation
- 2011-06-03 ES ES11789909.6T patent/ES2581557T3/es active Active
- 2011-06-03 JP JP2012518458A patent/JP5555320B2/ja not_active Expired - Fee Related
- 2011-06-03 EP EP11789909.6A patent/EP2578574B1/en not_active Not-in-force
- 2011-06-03 WO PCT/JP2011/062751 patent/WO2011152508A1/ja active Application Filing
- 2011-06-03 PT PT117899096T patent/PT2578574E/pt unknown
- 2011-06-03 CN CN201180027596.9A patent/CN102933559B/zh not_active Expired - Fee Related
- 2011-06-03 US US13/700,849 patent/US8906895B2/en not_active Expired - Fee Related
- 2011-06-03 CN CN201510015412.7A patent/CN104529910B/zh not_active Expired - Fee Related
- 2011-06-03 IN IN10925CHN2012 patent/IN2012CN10925A/en unknown
- 2011-06-03 TW TW100119614A patent/TWI492749B/zh not_active IP Right Cessation
- 2011-06-03 EA EA201291447A patent/EA024241B1/ru not_active IP Right Cessation
- 2011-06-03 BR BR112012030787-8A patent/BR112012030787A2/pt not_active IP Right Cessation
- 2011-06-03 AU AU2011259929A patent/AU2011259929B2/en not_active Ceased
- 2011-06-03 MX MX2012014149A patent/MX338024B/es active IP Right Grant
-
2012
- 2012-12-02 IL IL223377A patent/IL223377A/en active IP Right Grant
- 2012-12-11 ZA ZA2012/09372A patent/ZA201209372B/en unknown
-
2013
- 2013-06-19 HK HK13107169.5A patent/HK1179959A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2801417A1 (en) | 2011-12-08 |
| AU2011259929A1 (en) | 2013-01-17 |
| EP2578574A4 (en) | 2013-12-04 |
| CN104529910B (zh) | 2017-05-10 |
| EA024241B1 (ru) | 2016-08-31 |
| TWI492749B (zh) | 2015-07-21 |
| ES2581557T3 (es) | 2016-09-06 |
| AU2011259929B2 (en) | 2014-07-31 |
| JP5555320B2 (ja) | 2014-07-23 |
| MX338024B (es) | 2016-03-31 |
| EP2578574A1 (en) | 2013-04-10 |
| CA2801417C (en) | 2017-07-11 |
| HK1179959A1 (zh) | 2013-10-11 |
| CN102933559A (zh) | 2013-02-13 |
| CN104529910A (zh) | 2015-04-22 |
| US8906895B2 (en) | 2014-12-09 |
| KR20170078865A (ko) | 2017-07-07 |
| BR112012030787A2 (pt) | 2020-09-01 |
| ZA201209372B (en) | 2014-02-26 |
| JPWO2011152508A1 (ja) | 2013-08-01 |
| IL223377A0 (en) | 2013-03-05 |
| EP2578574B1 (en) | 2016-04-27 |
| PT2578574E (pt) | 2016-06-17 |
| WO2011152508A1 (ja) | 2011-12-08 |
| MX2012014149A (es) | 2013-02-27 |
| US20130225814A1 (en) | 2013-08-29 |
| TW201208688A (en) | 2012-03-01 |
| EA201291447A1 (ru) | 2013-05-30 |
| KR20130111512A (ko) | 2013-10-10 |
| IL223377A (en) | 2016-12-29 |
| CN102933559B (zh) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012CN10925A (zh) | ||
| TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| MA34818B1 (fr) | Anticorps anti-pcsk9 et procédés d'utilisation | |
| NZ601374A (en) | Stabilized antibody-containing liquid formulations | |
| MA34519B1 (fr) | Anticorps anti-fap et procédés d'utilisation | |
| AR094204A1 (es) | Composiciones para el cuidado oral que contienen haluros de acido amino | |
| MX352823B (es) | Formulaciones de proteinas que contienen aminoacidos. | |
| AR059964A1 (es) | Metodos para reducir la aglomeracion de proteina | |
| EP2315833B8 (en) | Vectors for delivery of light-sensitive proteins and methods of use | |
| SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| EP1740183B8 (en) | Novel use for pde5 inhibitors | |
| MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
| UA104677C2 (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательных путей | |
| NZ605873A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
| MA28985B1 (fr) | Analogues de loxapine et methodes d'utilisation | |
| CL2012002948A1 (es) | Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado. | |
| HN2008001859A (es) | Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida. | |
| SG162766A1 (en) | Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors | |
| MA34643B1 (fr) | Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique | |
| EA200900780A1 (ru) | Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства | |
| MY146803A (en) | Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors | |
| RS53408B (en) | PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION | |
| AU316238S (en) | Lawning applicator for microbiological cultures | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. |